PAPADOPOULOS, K. P.; OWONIKOKO, T. K.; JOHNSON, M. L.; BRANA, I.; GIL-MARTIN, M.; PEREZ, R. P.; MORENO, V.; SALAMA, A. K.; CALVO, E.; YEE, N. S.; SAFRAN, H.; GONZALEZ-MARTIN, A.; ALJUMAILY, R.; MAHADEVAN, D.; MOHAN, K. K.; LI, J.; STANKEVICH, E.; LOWY, I.; FURY, M. G.; HOMSI, J. Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, n. S1, p. S45, 2018. DOI: 10.25251/skin.2.supp.45. Disponível em: https://jofskin.org/index.php/skin/article/view/301. Acesso em: 22 jul. 2024.